Patents Assigned to GemVax AS
-
Publication number: 20160008438Abstract: Provided in the present invention is a peptide for preventing or treating sepsis. The peptide can improve symptoms of sepsis by inhibiting production of TNF, IL-1, and IL-6, which are cytokines that are related to sepsis, or can prevent or treat sepsis.Type: ApplicationFiled: May 10, 2013Publication date: January 14, 2016Applicants: KAEL-GEMVAX CO., LTD.Inventor: Sang Jae KIM
-
Publication number: 20160002613Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 6, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 6, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.Type: ApplicationFiled: September 17, 2013Publication date: January 7, 2016Applicant: GemVax & KAEL Co., Ltd.Inventor: Sang Jae KIM
-
Publication number: 20150353903Abstract: The present invention relates to composition for preventing or treating cachexia, and more specifically, to a composition for preventing or treating cachexia containing a peptide derived from a telomerase. The composition for preventing or treating cachexia, according to present invention, has the advantages of improving symptoms of cachexia, such as weight loss, anemia, edema, and loss of appetite, and has few side effects.Type: ApplicationFiled: May 10, 2013Publication date: December 10, 2015Applicants: KAEL-GEMVAX CO., LTD.Inventor: Sang Jae KIM
-
Publication number: 20150307859Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.Type: ApplicationFiled: September 17, 2013Publication date: October 29, 2015Applicant: GEMVAX & KAEL CO., LTD.Inventor: Sang Jae KIM
-
Publication number: 20150175978Abstract: The present disclosure relates to a composition for treating and preventing an rheumatoid arthritis, wherein the composition containing a peptide comprising amino acid sequence of SEQ ID NO: 1, a peptide having 80% or more sequence identity with the amino acid sequence of the peptide or a peptide which is a fragment thereof. According to the present invention, provided is a composition for prevention or treatment of rheumatoid arthritis having a. superior effect of treating and preventing rheumatoid arthritis with minimized side effect.Type: ApplicationFiled: May 10, 2013Publication date: June 25, 2015Applicants: KAEL-GEMVAX CO., LTD.Inventor: Sang Jae Kim
-
Publication number: 20150099692Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.Type: ApplicationFiled: May 7, 2013Publication date: April 9, 2015Applicants: KAEL-GEMBAX CO., LTD., GEMVAX ASInventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
-
Publication number: 20150099693Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.Type: ApplicationFiled: March 15, 2013Publication date: April 9, 2015Applicants: KAEL-GEMVAX CO., LTD., GEMVAX-ASInventors: Sang Jae Kim, Kyun Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
-
Patent number: 8614177Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.Type: GrantFiled: January 3, 2011Date of Patent: December 24, 2013Assignee: Gemvax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
-
Publication number: 20120269858Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: ApplicationFiled: May 31, 2012Publication date: October 25, 2012Applicant: GEMVAX ASInventors: Gustav GAUDERNACK, Stein SÆBØE-LARSSEN, Mona MØLLER, Jon Amund ERIKSEN
-
Patent number: 8193326Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognizing and destroying tumor cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: GrantFiled: March 5, 2008Date of Patent: June 5, 2012Assignee: GemVax ASInventors: Gustav Gaudernack, Stein Sæbøe-Larssen, Mona Møller, Jon Amund Eriksen
-
Publication number: 20110105721Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.Type: ApplicationFiled: January 3, 2011Publication date: May 5, 2011Applicant: GEMVAX ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
-
Patent number: 7863244Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.Type: GrantFiled: August 3, 2006Date of Patent: January 4, 2011Assignee: Gemvax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
-
Patent number: 7794723Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.Type: GrantFiled: January 17, 2006Date of Patent: September 14, 2010Assignee: GemVax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal, Stein Sæbøe-Larsen
-
Patent number: 7375117Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognizing and destroying tumor cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: GrantFiled: March 29, 2006Date of Patent: May 20, 2008Assignee: GemVax ASInventors: Gustav Gaudernack, Stein Sæøe-Larssen, Mona Møller, Jon Amund Eriksen
-
Patent number: 7192927Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.Type: GrantFiled: February 12, 2004Date of Patent: March 20, 2007Assignee: Gemvax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
-
Publication number: 20070004632Abstract: Peptides from cancer related protein products of frameshift mutated genes which eliciting T cellular immunity for use in cancer vaccines and compositions for anticancer treatment.Type: ApplicationFiled: August 3, 2006Publication date: January 4, 2007Applicant: GEMVAX ASInventors: Gustav Gaudernack, Jon Eriksen, Mona Moller, Marianne Gjertsen, Ingvil Saeterdal
-
Publication number: 20060194731Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: ApplicationFiled: March 29, 2006Publication date: August 31, 2006Applicant: GemVax AsInventors: Gustav Gaudernack, Stein Saeboe-Larssen, Mona Moller, Jon Eriksen
-
Patent number: 7078416Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: GrantFiled: December 18, 2001Date of Patent: July 18, 2006Assignee: GemVax ASInventors: Gustav Gaudernack, Stein Sæbøe-Larssen, Mona Møller, Jon Amund Eriksen
-
Publication number: 20060106196Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.Type: ApplicationFiled: January 17, 2006Publication date: May 18, 2006Applicant: GemVax ASInventors: Gustav Gaudernack, Jon Eriksen, Mona Moller, Marianne Gjertsen, Ingvil Saeterdal, Stein Saeboe-Larsen
-
Patent number: 7030211Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.Type: GrantFiled: June 30, 1990Date of Patent: April 18, 2006Assignee: GemVax ASInventors: Gustay Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal, Stein Sæbøe-Larsen